ABSTRACT
Autotaxin (ATX) is a secreted enzyme playing a major role in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl choline (LPC). The ATX-LPA signaling axis arouses a high interest in the drug discovery industry as it has been implicated in several diseases including cancer, fibrotic diseases, and inflammation, among others. An imidazo[1,2-a]pyridine series of ATX inhibitors was identified out of a high-throughput screening (HTS). A cocrystal structure with one of these compounds and ATX revealed a novel binding mode with occupancy of the hydrophobic pocket and channel of ATX but no interaction with zinc ions of the catalytic site. Exploration of the structure-activity relationship led to compounds displaying high activity in biochemical and plasma assays, exemplified by compound 40. Compound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.
Subject(s)
Imidazoles/chemistry , Imidazoles/pharmacology , Phosphodiesterase Inhibitors/chemistry , Phosphodiesterase Inhibitors/pharmacology , Phosphoric Diester Hydrolases/metabolism , Pyridines/chemistry , Pyridines/pharmacology , Animals , Humans , Imidazoles/pharmacokinetics , Lysophosphatidylcholines/metabolism , Lysophospholipids/metabolism , Male , Mice , Molecular Docking Simulation , Phosphodiesterase Inhibitors/pharmacokinetics , Phosphoric Diester Hydrolases/chemistry , Pyridines/pharmacokinetics , Rats , Rats, Sprague-Dawley , Structure-Activity RelationshipABSTRACT
Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disease areas including pulmonary fibrosis. Structural modifications of the known autotaxin inhibitor lead compound 1, to attenuate hERG inhibition, remove CYP3A4 time-dependent inhibition, and improve pharmacokinetic properties, led to the identification of clinical candidate GLPG1690 (11). Compound 11 was able to cause a sustained reduction of LPA levels in plasma in vivo and was shown to be efficacious in a bleomycin-induced pulmonary fibrosis model in mice and in reducing extracellular matrix deposition in the lung while also reducing LPA 18:2 content in bronchoalveolar lavage fluid. Compound 11 is currently being evaluated in an exploratory phase 2a study in idiopathic pulmonary fibrosis patients.
Subject(s)
Idiopathic Pulmonary Fibrosis/drug therapy , Imidazoles/therapeutic use , Phosphoric Diester Hydrolases/drug effects , Pyrimidines/therapeutic use , Animals , Humans , Imidazoles/pharmacology , Mice , Mice, Knockout , Phosphoric Diester Hydrolases/genetics , Pyrimidines/pharmacology , RatsABSTRACT
Structural modification performed on a 4-methyl-4-(4-hydroxyphenyl)hydantoin series is described which resulted in the development of a new series of 4-(hydroxymethyl)diarylhydantoin analogues as potent, partial agonists of the human androgen receptor. This led to the identification of (S)-(-)-4-(4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile ((S)-(-)-18a, GLPG0492) evaluated in vivo in a classical model of orchidectomized rat. In this model, (-)-18a exhibited anabolic activity on muscle, strongly dissociated from the androgenic activity on prostate after oral dosing. (-)-18a has very good pharmacokinetic properties, including bioavailability in rat (F > 50%), and is currently under evaluation in phase I clinical trials.
Subject(s)
Androgens/chemical synthesis , Hydantoins/chemical synthesis , Anabolic Agents/chemical synthesis , Anabolic Agents/chemistry , Anabolic Agents/pharmacology , Androgen Receptor Antagonists/chemical synthesis , Androgen Receptor Antagonists/chemistry , Androgen Receptor Antagonists/pharmacology , Androgens/chemistry , Androgens/pharmacology , Animals , Biological Availability , Drug Partial Agonism , HeLa Cells , Humans , Hydantoins/chemistry , Hydantoins/pharmacology , Male , Models, Molecular , Molecular Conformation , Muscle, Skeletal/anatomy & histology , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Orchiectomy , Organ Size/drug effects , Prostate/anatomy & histology , Prostate/drug effects , Prostate/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Stereoisomerism , Structure-Activity Relationship , Transcriptional Activation/drug effectsABSTRACT
The development of asymmetric Morita-Baylis-Hillman (MBH) reactions has evolved dramatically over the past few years, parallel to the emerging concept of bifunctional organocatalysis. Whereas organocatalysis is starting to compete with metal-based catalysis in several important organic transformations, the MBH reaction belongs to a group of prototypical reactions in which organocatalysts already display superiority over their metal-based counterparts. This Minireview summarizes recent mechanistic insights and advances in the design and synthesis of small organic molecules for enantioselective MBH and aza-MBH reactions.